Cost-effectiveness Of Dolutegravir- Versus Efavirenz-based First-line Antiretroviral Treatments And Health-related Quality Of Life Of Adults With Hivaids In Ethiopia

Background: In Ethiopia, the dolutegravir (DTG)-based regimen is as of now favored rnover the efavirenz (EFV)-based regimen in the treatment of patients with human rnimmunodeficiency virus (HIV)/acquired immune-deficiency syndrome (AIDS). rnObjective: To determine the cost-effectiveness of DTG- versus EFV-based first-line rntreatment and health-related quality of life among Ethiopian adults with HIV/AIDS. rnMethods: Cost-utility analysis was done using a microsimulation model. The health-rnrelated utility value was obtained from adult HIV/AIDS patients receiving antiretroviral rntreatment at Tikur Anbessa Specialized Hospital. Mann-Whitney U and Kruskal-Wallis rntests were done to compare utility values based on patient characteristics. Incremental rncost-effectiveness ratio (ICER) was used to determine cost-effectiveness of the rnproposed regimens and deterministic sensitivity analysis was conducted to assess the rnparameter uncertainty in cost utility analysis. rnResults: Median utility values of HIV/AIDS patients were 0.94 (interquartile range rn(IQR) =0.87, 1) and 80% (IQR= 70%, 90%) on the EuroQol-5 dimensions (EQ-5D) rnindex and EuroQol-visual analog scales (EQ-VAS) score respectively. Comorbidity, rncluster of differentiation 4 and number of medicines were significantly associated with rnEQ-5D and EQ-VAS values with, p

Get Full Work

Report copyright infringement or plagiarism